Advances in pancreatic cancer research: Moving towards early detection

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11241-11248

  He, Xiang Yi ^a   Yuan, Yao Zong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diabetes mellitus; Early detection; Pancreatic cancer; Pancreatic ductal adenocarcinoma

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; MICRORNA; TUMOR MARKER;

CANCER SCREENING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DIABETES MELLITUS; EARLY DIAGNOSIS; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOGENESIS; REVIEW; BLOOD; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; GENETIC SCREENING; GENETICS; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

CARCINOMA, PANCREATIC DUCTAL; DIABETES MELLITUS; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84909594673     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11241     Document Type: Review

References (83)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/ caac.21166]
2. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc.2009.236]
3. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin 2013; 63: 318-348 [PMID: 23856911 DOI: 10.3322/caac.21190]
4. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]
5. Cooper CL, O'Toole SA, Kench JG. Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology 2013; 45: 286-304 [PMID: 23442735 DOI: 10.1097/PAT.0b013e32835f2205]
6. Ottenhof NA, Milne AN, Morsink FH, Drillenburg P, Ten Kate FJ, Maitra A, Offerhaus GJ. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med 2009; 133: 375-381 [PMID: 19260743 DOI: 10.1043/1543-2165-133.3.375]
7. Macgregor-Das AM, Iacobuzio-Donahue CA. Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 2013; 107: 8-14 [PMID: 22806689 DOI: 10.1002/jso.23213]
8. Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008; 135: 724-728 [PMID: 18692502 DOI: 10.1053/ j.gastro.2008.07.033]
9. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio- Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321 : 1801-1806 [PMID: 18772397 DOI: 10.1126/science. 1164368]
10. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405 [PMID: 23103869 DOI: 10.1038/nature11547]
11. Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, Szabo C, Zhang L, Eckloff BW, Petersen GM, Scherer SE, Gibbs RA, McWilliams RR, Vasmatzis G, Couch FJ. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013; 145: 1098-1109.e1 [PMID: 23912084 DOI: 10.1053/j.gastro.2013.07.049]
12. Ben QW, Jin XL, Liu J, Cai X, Yuan F, Yuan YZ. Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol Rep 2011; 25 : 709-716 [PMID: 21225237 DOI: 10.3892/or.2011.1140]
13. Huang J, Yao WY, Zhu Q, Tu SP, Yuan F, Wang HF, Zhang YP, Yuan YZ. XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci 2010; 101: 559-567 [PMID: 19922503 DOI: 10.1111/j.1349-7006.2009.01396.x]
14. Zhou L, Zhang R, Zhang L, Yao W, Li J, Yuan Y. Angiotensinconverting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett 2011; 307: 18-25 [PMID: 21481527 DOI: 10.1016/j.canlet.2011.03.011]
15. Liu J, Ben QW, Yao WY, Zhang JJ, Chen DF, He XY, Li L, Yuan YZ. BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front Biosci (Landmark Ed) 2012; 17: 2541-2549 [PMID: 22652796 DOI: 10.2741/4069]
16. Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W, Zhang Y. Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun 2009; 380: 11-16 [PMID: 19138673 DOI: 10.1016/j.bbrc.2008.12.171]
17. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, Yuan YZ. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010; 17: 2213-2221 [PMID: 20162456 DOI: 10.1245/s10434-010-0955-x]
18. He X, Zheng Z, Li J, Ben Q, Liu J, Zhang J, Ji J, Yu B, Chen X, Su L, Zhou L, Liu B, Yuan Y. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/ uPA. Carcinogenesis 2012; 33: 555-562 [PMID: 22223849 DOI: 10.1093/carcin/bgs002]
19. Papaconstantinou IG, Lykoudis PM, Gazouli M, Manta A, Polymeneas G, Voros D. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas 2012; 41: 671-677 [PMID: 22695087 DOI: 10.1097/MPA.0b013e31823c9d21]
20. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 2013; 8: e71978 [PMID: 23991015 DOI: 10.1371/journal. pone.0071978]
21. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-4538 [PMID: 20460539 DOI: 10.1158/0008-5472.CAN-09-4467]
22. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, Takahata S, Toma H, Nagai E, Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8 : 1067-1074 [PMID: 19435867 DOI: 10.1158/1535-7163.MCT-08-0592]
23. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroR-NA- 21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008; 12: 2171-2176 [PMID: 18642050 DOI: 10.1007/s11605-008-0584-x]
24. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908 [PMID: 17473300 DOI: 10.1001/ jama.297.17.1901]
25. Liu M, Du Y, Gao J, Liu J, Kong X, Gong Y, Li Z, Wu H, Chen H. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Pancreas 2013; 42: 1169-1181 [PMID: 24048456 DOI: 10.1097/MPA.0b013e3182962acb]
26. Zhao G, Zhang JG, Shi Y, Qin Q, Liu Y, Wang B, Tian K, Deng SC, Li X, Zhu S, Gong Q, Niu Y, Wang CY. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One 2013; 8: e73803 [PMID: 24040078 DOI: 10.1371/journal. pone.0073803]
27. Zhang G, Zhou H, Xiao H, Liu Z, Tian H, Zhou T. MicroR-NA- 92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci 2014; 59: 98-107 [PMID: 24026406 DOI: 10.1007/s10620-013-2858-8]
28. Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC, Yao Q. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res 2013; 19: 5901-5913 [PMID: 23989979 DOI: 10.1158/1078-0432. CCR-12-3776]
29. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108: 361-369 [PMID: 23329235 DOI: 10.1038/bjc.2012.546]
30. Su A, He S, Tian B, Hu W, Zhang Z. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One 2013; 8: e71309 [PMID: 23967190 DOI: 10.1371/journal. pone.0071309]
31. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, Chen Z, Meng Z. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013; 145: 1133-1143.e12 [PMID: 23916944 DOI: 10.1053/j.gastro.2013.07.048]
32. Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 2009; 45: 3104-3118 [PMID: 19818597 DOI: 10.1016/ j.ejca.2009.09.014]
33. Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, Kobayashi S, Mori M, Doki Y. MicroRNA-29a induces resistance to gemcitabine through the Wnt/â-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 2013; 43: 1066-1072 [PMID: 23900458 DOI: 10.3892/ijo.2013.2037]
34. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-4276 [PMID: 22896693 DOI: 10.1158/1078-0432. CCR-11-3114]
35. Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013; 144: 1210-1219 [PMID: 23622130 DOI: 10.1053/j.gastro.2012.11.037]
36. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G. Hypoxia triggers hedgehog-mediated tumorstromal interactions in pancreatic cancer. Cancer Res 2013; 73 : 3235-3247 [PMID: 23633488 DOI: 10.1158/0008-5472. CAN-11-1433]
37. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
38. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88-95 [PMID: 19111249 DOI: 10.1016/S1470-2045(08)70337-1]
39. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19: F9-F26 [PMID: 22843556 DOI: 10.1530/ ERC-12-0105]
40. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012; 51: 64-74 [PMID: 22162232 DOI: 10.1002/mc.20771]
41. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083 [PMID: 15886696 DOI: 10.1038/sj.bjc.6602619]
42. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-197 [PMID: 21104117 DOI: 10.1007/s10552-010-9686-3]
43. Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S, Wang K. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 2011; 47: 248-254 [PMID: 20709528 DOI: 10.1016/j.ejca.2010.07.010]
44. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134 : 981-987 [PMID: 18395079 DOI: 10.1053/j.gastro.2008.01.039]
45. He XY, Li JF, Yao WY, Yuan YZ. Resolution of new-onset diabetes after radical pancreatic resection predicts long-term survival in patients with pancreatic ductal cell adenocarcinoma. Ann Surg Oncol 2013; 20: 3809-3816 [PMID: 23943021 DOI: 10.1245/s10434-013-3095-2]
46. Wu JM, Kuo TC, Yang CY, Chiang PY, Jeng YM, Huang PH, Tien YW. Resolution of diabetes after pancreaticoduodenectomy in patients with and without pancreatic ductal cell adenocarcinoma. Ann Surg Oncol 2013; 20 : 242-249 [PMID: 22864799 DOI: 10.1245/s10434-012-2577-y]
47. Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010; 11: 334-335 [PMID: 20601806]
48. Cannon RM, LeGrand R, Chagpar RB, Ahmad SA, Mc- Claine R, Kim HJ, Rupp C, Cho CS, Brinkman A, Weber S, Winslow ER, Kooby DA, Chu CK, Staley CA, Glenn I, Hawkins WG, Parikh AA, Merchant NB, McMasters KM, Martin RC, Callender GG, Scoggins CR. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) 2012; 14: 228-235 [PMID: 22404260 DOI: 10.1111/j.1477-2574.2011.00432.x]
49. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, insulin resistance, impaired pancreatic â-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013; 105: 1027-1035 [PMID: 23847240 DOI: 10.1093/jnci/djt123]
50. Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, Xia L, Wang X, Noguchi N, Yoshikawa T, Uruno A, Yao W, Yuan Y. Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer 2010; 127: 1795-1803 [PMID: 20099282 DOI: 10.1002/ijc.25188]
51. Osman MA, Sarkar FH, Rodriguez-Boulan E. A molecular rheostat at the interface of cancer and diabetes. Biochim Biophys Acta 2013; 1836: 166-176 [PMID: 23639840 DOI: 10.1016/j.bbcan.2013.04.005]
52. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488 [PMID: 19375425 DOI: 10.1053/j.gastro.2009.04.013]
53. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012; 96: 187-195 [PMID: 22245693 DOI: 10.1016/j.diabres.2011.12.028]
54. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539-6545 [PMID: 19679549 DOI: 10.1158/0008-5472.CAN-09-0418]
55. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 510-59; quiz 520 [PMID: 23399556 DOI: 10.1038/ajg.2013.7]
56. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011; 1815: 44-64 [PMID: 20888394 DOI: 10.1016/j.bbcan.2010.09.002]
57. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24: 252-258 [PMID: 16344318 DOI: 10.1200/JCO.2005.02.8282]
58. Märten A, Büchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother 2010; 33: 219-224 [PMID: 20139773 DOI: 10.1097/ CJI.0b013e3181bed29f]
59. Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 2010; 45: 52-59 [PMID: 19789838 DOI: 10.1007/s00535-009-0114-y]
60. Takano S, Sogawa K, Yoshitomi H, Shida T, Mogushi K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Ishihara T, Tanaka H, Yokosuka O, Nomura F, Miyazaki M. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer 2010; 103: 223-231 [PMID: 20551957 DOI: 10.1038/sj.bjc.6605734]
61. Wang F, Chen L, Ding W, Wang G, Wu Y, Wang J, Luo L, Cong H, Wang Y, Ju S, Shao J, Wang H. Serum APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Lab Med 2011; 49 : 1715-1719 [PMID: 21612541 DOI: 10.1515/ CCLM.2011.608]
62. He XY, Liu BY, Yao WY, Zhao XJ, Zheng Z, Li JF, Yu BQ, Yuan YZ. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer. J Dig Dis 2011; 12: 131-137 [PMID: 21401899 DOI: 10.1111/j.1751-2980.2011.00488.x]
63. Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, Diamandis EP. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics 2013; 12: 2820-2832 [PMID: 23798558 DOI: 10.1074/mcp.M112.023507]
64. Pardo M, García A, Thomas B, Piñeiro A, Akoulitchev A, Dwek RA, Zitzmann N. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer 2006; 119: 1014-1022 [PMID: 16570276 DOI: 10.1002/ijc.21942]
65. Chen Y, Kang M, Lu W, Guo Q, Zhang B, Xie Q, Wu Y. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. J Cancer Res Clin Oncol 2012; 138: 1463-1474 [PMID: 22526154 DOI: 10.1007/ s00432-012-1205-3]
66. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8: 241 [PMID: 18706098 DOI: 10.1186/1471-2407-8-241]
67. Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer 2013; 13: 404 [PMID: 24007603 DOI: 10.1186/1471-2407 -13-404]
68. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-816 [PMID: 21325298 DOI: 10.1158/1078-0432.CCR-10-0248]
69. Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ, Suriawinata AA, Tsongalis GJ. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet 2013; 206: 217-221 [PMID: 23933230 DOI: 10.1016/j.cancergen.2013.05.020]
70. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56 : 603-612 [PMID: 20093556 DOI: 10.1373/ clinchem.2009.137364]
71. Wan C, Shen Y, Yang T, Wang T, Chen L, Wen F. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci 2012; 8: 749-755 [PMID: 23185182 DOI: 10.5114/ aoms.2012.31609]
72. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58 : 610-618 [PMID: 22194634 DOI: 10.1373/ clinchem.2011.172767]
73. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012; 131: 683-691 [PMID: 21913185 DOI: 10.1002/ijc.26422]
74. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with lowstage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600-3610 [PMID: 23697990 DOI: 10.1158/1078-0432.CCR-12-3092]
75. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105: 1733-1740 [PMID: 22045190 DOI: 10.1038/bjc.2011.453]
76. Kamande JW, Hupert ML, Witek MA, Wang H, Torphy RJ, Dharmasiri U, Njoroge SK, Jackson JM, Aufforth RD, Snavely A, Yeh JJ, Soper SA. Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer. Anal Chem 2013; 85: 9092-9100 [PMID: 23947293 DOI: 10.1021/ac401720k]
77. Iwanicki-Caron I, Basile P, Toure E, Antonietti M, Lecleire S, Di Fiore A, Oden-Gangloff A, Blanchard F, Lemoine F, Di Fiore F, Sabourin JC, Michel P. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Am J Gastroenterol 2013; 108: 152-155 [PMID: 23287955 DOI: 10.1038/ajg.2012.367]
78. Sabbaghian MS, Rothberger G, Alongi AP, Gagner JP, Goldberg JD, Rolnitzky L, Chiriboga L, Hajdu CH, Zagzag D, Basch R, Shamamian P. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Res 2010; 30: 2911-2917 [PMID: 20683032]
79. Tjensvoll K, Nordga˚rd O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer 2014; 134: 1-8 [PMID: 23447365 DOI: 10.1002/ijc.28134]
80. Ren C, Chen H, Han C, Jin G, Wang D, Wang D, Tang D. Detection and molecular analysis of circulating tumor cells for early diagnosis of pancreatic cancer. Med Hypotheses 2013; 80: 833-836 [PMID: 23587480 DOI: 10.1016/j.mehy.2013.03.027]
81. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 2013; 24: 2057-2061 [PMID: 23676420 DOI: 10.1093/annonc/mdt176]
82. Cen P, Ni X, Yang J, Graham DY, Li M. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta 2012; 1826: 350-356 [PMID: 22683404 DOI: 10.1016/j.bbcan.2012.05.007]
83. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg 2008; 15 : 189-195 [PMID: 18392713 DOI: 10.1007/s00534-007-1250-5]